The Semaglutide Treatment Effect in People with obesity (STEP) program, a phase III randomized clinical trial (RCT), was conducted in patients with T2D, obesity, and various metabolic disorders
Furthermore, the presence of AHK-Cu may reduce the number of apoptotic DPCs, potentially increasing the Bcl-2/Bax ratio and lowering the levels of cleaved caspase-3 and PARP, two markers of cell death[2]
Rodent (diet-induced obesity, 11 days) Subcutaneous 5-Amino-1MQ at roughly 34 mg/kg/day reduced body weight and white adipose mass without changing food intake or lean mass
Research also points to potential improvements in: Menopausal symptoms Reproductive health Breast cancer risk Lets discuss proposed mechanisms of action to allow for a deeper understanding of its benefits
Older researchers supplementing GHK-CU are restoring something their bodies have lost